phone: +48 22 721 40 00   /  fax: +48 22 721 13 33  /   bioinfo@bioton.pl



Current report (24/2019) dated 07.09.2019, time 12:27 UTC



Termination of the agreement for the commercialization of recombinant human insulin in the territory of Brazil.

Download file

   RB 24 2019 EN

 

 


 

Contact for media:

phone.: +48 577 677 988
e-mail: media@bioton.pl

© 2019 BIOTON S.A.